Understanding how patients with heart failure with preserved ejection fraction (HFPEF) die provides insight into the natural history and pathophysiology of this complex syndrome, thereby allowing ...

For patients with HFPEF and other underlying comorbidities ... as defined by prespecified clinical and echocardiographic criteria, and hospitalized for a cardiovascular cause within the previous ...

An established cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM), mavacamten (Camzyos) showed potential for ...

Which mineralocorticoid receptor antagonists (MRAs; ie, steroidal, nonsteroidal) are currently indicated or used for treating heart failure with midrange ejection fraction (HFmrEF) and HF failure ...

Novel therapies for HFmrEF and HFpEF aim to improve symptom management and patient outcomes, addressing current treatment limitations. Emerging treatments could reduce hospitalization rates and ...

USA: A recent study from the EMBARK-HFpEF trial has revealed promising results regarding using mavacamten, a cardiac myosin ...

Among the benefits of semaglutide, the GLP-1 receptor agonist may protect against heart failure events in patients with type 2 diabetes and CKD.

Postmarket data on MitraClip lend further support to the idea that this subgroup fares as well as the overall SMR population.

Further editorial criteria may be applicable for different kinds of papers, as follows: Articles published in Nature have an exceptionally wide impact, both among scientists and, frequently ...

HFpEF is a condition in which heart muscles ... on a 100-point health scale based on a range of heart failure-related criteria. It also improved physical limitations and exercise function in ...

The trial was done in adults with obesity and heart failure with preserved ejection fraction (HFpEF). The data, posted online on August 1, has not yet been published in a peer-reviewed journal.